Latest news with #GLP1RAs
Medscape
5 days ago
- Business
- Medscape
GLP-1 Users Should Fast 24 Hours Before Anesthesia
Patients taking the new class of weight-loss drugs do not need to stop these medications prior to procedures requiring anesthesia, but they should adhere to longer preoperative fasting times, according to a new multidisciplinary consensus statement. The statement, led by the Society for Perioperative Assessment and Quality Improvement, recommends patients without significant gastrointestinal symptoms associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) should fast from solid foods for 24 hours and stick to clear liquids prior to a procedure requiring anesthesia. This extended fasting time can help mitigate aspiration risk in these patients with delayed gastric emptying while retaining the benefits of continuing GLP-1 RAs, such as improved glycemic control. The statement is 'the first to provide recommendations for perioperative management of patients taking GLP-1 RAs based on an in-depth systematic literature review of both clinical perioperative studies and gastric emptying data,' Adriana Oprea, MD, the first author of the document, and her colleagues wrote. Changing Guidance In June 2023, the American Society of Anesthesiologists (ASA) released the first guidance statement regarding preoperative management of patients on GLP-1 RAs, after some case reports documented aspiration events in these patients. While the number of these events is generally low and rates of aspiration appear to be similar between patients on GLP-1 RAs and the general population, 'people got really worried with these drugs because of [the] delayed gastric emptying,' Oprea, an associate professor of anesthesiology at Yale School of Medicine in New Haven, Connecticut, told Medscape Medical News . The 2023 ASA guidance recommended holding GLP-1 RAs for one half-life — a week for patients on long-acting medication and a day for short-acting GLP-1s. Due to a lack of adequate evidence at the time, the document suggested these patients should follow the standard ASA fasting guidelines of 8 hours after a full meal. However, evidence suggests stopping GLP-1s for one half-life is not enough for the effects on gastric emptying to subside, according to the new statement. For longer-acting drugs like dulaglutide, semaglutide, and tirzepatide, patients would need to discontinue these medications for several weeks to restore normal gastrointestinal motility. For patients with type 2 diabetes, discontinuation of these medications over this period could lead to poor glycemic control, which is linked to worse postoperative outcomes. For patients taking GLP-1 RAs for weight loss, restarting these medications can result in increased gastrointestinal symptoms, Oprea said, such as nausea, vomiting, diarrhea, or constipation. 'Because adverse effects are more prevalent at higher GLP-1 RA doses, discontinuation of these medications might lead to a high likelihood of side effects upon medication reinitiation or require reinitiation of therapy at lower doses followed by dose reescalation,' Oprea's group wrote. 'This is logistically difficult for both patients and treating clinicians.' In October 2024, the ASA, along with other professional societies, published updated practice guidance stating GLP-1 RAs may be continued preoperatively in patients without an elevated risk for delayed gastric emptying and aspiration. Those defined as 'higher risk' included patients in the escalation phase, on weekly dosing, on higher doses, and with gastrointestinal symptoms. The guidance advised these patients at higher risk for delayed stomach emptying can help mitigate aspiration risk by following a 24-hour liquid diet. This updated guidance also received some criticism. 'As of yet, no studies have reported a difference in the incidence of increased residual gastric content that would justify treating patients differently on the basis of dose regimen and/or treatment phase,' wrote Glenio B. Mizubuti, MD, PhD, of the Kingston General Hospital, in Kingston, Ontario, Canada, and his colleagues in a letter to Anesthesiology . 'Similarly, the absence of ongoing digestive symptoms, while somewhat reassuring, should not be taken as a definitive sign of an empty stomach in GLP-1 RA users,' they wrote. Continue Meds, Extend Fasting Times This new consensus statement, published last month in the British Journal of Anaesthesia , recommends patients doing well on GLP-1 RAs should continue these medications preoperatively and follow a clear liquid diet for 24 hours before procedures requiring anesthesia. The recommendations were based on a systematic review of 112 studies and a modified Delphi process and were co-sponsored and endorsed by the American Association of Clinical Endocrinology. 'From our review of the literature, we feel that the fasting times are the most important factor that could decrease the risk of having residual gastric content in the stomach in a patient on GLP-1 RAs when they're scheduled to have a procedure that requires anesthesia,' Oprea said. The consensus also recommends patients on GLP-1s fast from high-carbohydrate-content clear liquids (containing 10% or more glucose) for 8 hours before and stop drinking any liquids four hours before these procedures. Inpatient and outpatients can restart GLP-1 RAs when they resume their original diets. Patients with significant gastrointestinal symptoms including severe nausea, vomiting, and inability to tolerate oral intake should postpone elective procedures that require anesthesia and refer to their prescribing physician for diet and medication modifications to manage symptoms, the authors advised. 'Our recommendation for a clear liquid diet for 24 hours preprocedurally might appear overly restrictive. However, evidence points to the safety of this approach in patients on GLP-1 RAs,' they wrote.
Medscape
5 days ago
- Health
- Medscape
Patients With HS, Obesity Report Improvements With GLP-1 RAs
In a survey of 22 patients with hidradenitis suppurativa (HS), more than two thirds reported symptom improvement after treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs). METHODOLOGY: Researchers conducted a cross-sectional survey of 22 adults (average age, 45 years; 90.9% women) with HS who were treated with GLP-1 RAs at the University of Pennsylvania's Dermatology Department between January 2019 and August 2024. Most participants were non-Hispanic (90.9%), 54.5% were Black, and 36.4% were White; 89.5% were classified as overweight or having obesity. GLP-1 RAs prescriptions were semaglutide (40.9%), tirzepatide (36.4%), dulaglutide (18.2%), or liraglutide (4.5%), with an average treatment duration of 17 months (range, 2-108 months). Primary outcomes were HS severity and quality of life. TAKEAWAY: Most participants (77.3%) achieved weight loss averaging 31 lb; 68.2% reported improvement in HS-specific health, while 31.8% reported no change in their condition. Patient-reported symptom improvements included reduced flares (61.9%), new lesions (66.7%), pain (52.4%), drainage (61.9%), itch (47.6%), and odor (42.9%). Common side effects included gastrointestinal symptoms, allergic reactions, headaches, menstrual spotting, and appetite suppression. Nearly 60% of patients reported that HS had less impact on their daily activities, with the same percentage stating they would recommend GLP-1 RAs to other patients. IN PRACTICE: 'These data suggest GLP-1 RAs may play an important adjunctive role in the treatment of HS, particularly given the high prevalence of obesity and diabetes in the HS population,' the study authors wrote. 'Randomized controlled studies with robust patient and dermatologist-reported endpoints,' they added, 'are needed to confirm these findings and establish clinical guidelines for use of GLP-1 RAs' in HS. SOURCE: The study was led by Radhika Gupta, BA, University of Pennsylvania, Philadelphia. It was published online on May 29 in JAAD International . LIMITATIONS: Study limitations included small size, lack of clinician assessment, high nonresponse rate, and potential recall bias. DISCLOSURES: The study received funding through a philanthropic gift for HS research. Gupta disclosed being a consultant for Cabaletta Bio. One author reported receiving research funding from Amgen, Boehringer Ingelheim, Cabaletta Bio, and InflaRx. Another author reported being a consultant for Sonoma Biotherapeutics, and the fourth author reported being a consultant for Vertex Pharmaceuticals.
Yahoo
22-05-2025
- Business
- Yahoo
Semaglutide (Ozempic, Wegovy, Rybelsus) Market Trends Analysis and Growth Report 2025-2035: Emerging Markets and Oral Formulations Present New Frontiers for Expansion
The Semaglutide Market, valued at USD 28.43 Billion in 2024, is anticipated to reach USD 93.60 Billion by 2035, growing at a CAGR of 10.47%. Growth drivers include the rising prevalence of diabetes and obesity, regulatory approvals, and expanding clinical indications. Key players like Novo Nordisk lead the market, which is influenced by patent protection and competitive dynamics in drug formulations. Semaglutide Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2025 - 2035" report has been added to semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments. The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market Market Report Highlights Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes. Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies. Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations. Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy. Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires. In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Company Profiles Novo Nordisk Eli Lilly Viking Therapeutics Lexicon Pharmaceuticals Biocon AstraZeneca Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2035 Estimated Market Value (USD) in 2024 $28.43 Billion Forecasted Market Value (USD) by 2035 $93.6 Billion Compound Annual Growth Rate 10.4% Regions Covered Global Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Snapshot2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. Semaglutide Market Variables, Trends, & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Business Environment Analysis3.3.1. Industry Analysis - Porter's Five Forces Analysis3.3.2. PESTLE Analysis3.3.3. Pipeline Analysis, by Phase3.3.4. Patent Expiry Analysis3.3.5. Pricing Analysis3.3.6. Competitive Landscape: Emerging Biosimilars in The Post-Patent Semaglutide MarketChapter 4. Semaglutide Market: Product Business Analysis4.1. Product Market Share, 2024 & 20354.2. Product Segment Dashboard4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)4.4. Ozempic4.5. Wegovy4.6. Rybelsus4.7. OthersChapter 5. Semaglutide Market: Application Business Analysis5.1. Application Market Share, 2024 & 20355.2. Application Segment Dashboard5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)5.4. Type 2 Diabetes Mellitus5.5. Obesity5.6. OthersChapter 6. Semaglutide Market: Route of Administration Business Analysis6.1. Route of Administration Market Share, 2024 & 20356.2. Route of Administration Segment Dashboard6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)6.4. Parenteral6.5. OralChapter 7. Semaglutide Market: Distribution Channel Business Analysis7.1. Distribution Channel Market Share, 2024 & 20357.2. Distribution Channel Segment Dashboard7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)7.4. Hospital Pharmacies7.5. Retail Pharmacies7.6. Online PharmaciesChapter 8. Semaglutide Market: Regional Estimates & Trend Analysis8.1. Regional Market Share Analysis, 2024 & 20358.2. Regional Market Dashboard8.3. Market Size & Forecasts Trend AnalysisChapter 9. Competitive Landscape9.1. Participant Overview9.2. Company Market Position Analysis9.3. Company Categorization9.4. Strategy Mapping For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Semaglutide Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
14-05-2025
- Health
- Fox News
Weight-loss drugs' impact on cancer risk revealed in new study
Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, meningioma, adenocarcinoma of esophagus; stomach, colorectal, liver or bile duct, gallbladder, pancreas, uterus, ovary, renal-cell kidney, thyroid, and postmenopausal breast cancer, according to the Centers for Disease Control and Prevention (CDC). Researchers at Clalit Health Services in Tel Aviv, Israel, conducted an observational study of the medical records of 6,356 participants aged 24 and older who had obesity and diabetes, with no history of obesity-related cancer. Between 2010 and 2018, half of the participants took GLP-1 receptor agonists (GLP-1 RAs) — injectable medications for obesity and type 2 diabetes — with at least six drug purchases within 12 months. The other half underwent bariatric metabolic surgery (BMS). After adjusting for other factors, the researchers determined that ORC occurred in 5.62 cases per 1,000 person-years in those who had the surgery, and in 5.89 cases per 1,000 person-years among those who took GLP-1s. Overall, the study determined that "the direct effect of GLP1-RAs compared to BMS on the risk for ORC beyond their effects on weight-loss is estimated as 41% relative risk reduction." The findings were published in the journal eClinicalMedicine. "The results point at the existence of additional pathways beyond weight loss in which GLP-1RAs contribute to the decreased risk for obesity-related cancer," lead study author Yael Wolff Sagy, PhD, head of research at Clalit Health Services, told Fox News Digital. Niketa Patel, professor of molecular medicine with the USF Health Morsani College of Medicine in Tampa, Florida, noted that obesity is associated with chronic inflammation. "GLP1-RAs are shown to reduce inflammation and thus decrease the risk of developing ORC," she told Fox News Digital. (Patel was not involved in the study.) "The anti-inflammatory properties of these medications address a known risk factor for various cancers." "Bottom line: Obesity can cause certain cancers, and treatment of obesity with GLP1-RA reduces the risk of only obesity-related cancers." Dr. Britta Reierson, MD, medical director of knownwell, a provider of metabolic health services, said there are several ways in which GLP-1 RAs could have cancer mitigation properties. "First, the anti-inflammatory properties of these medications address a known risk factor for various cancers," the Minnesota-based doctor, who also was not part of the research, told Fox News Digital. "Second, the metabolic regulation and improvement in metabolic health from these medications, including lowering blood glucose levels and decreasing insulin resistance, can reduce cancer risk." Emerging evidence also suggests that GLP-1 RAs may have direct anti-tumor effects, Reierson noted — "potentially through modulation of immune responses and epigenetic changes (changes that occur to gene expression and are passed down to future generations)." Research suggests that GLP-1 medications help reduce inflammation not just through weight loss, but also in other organs of the body, such as the heart, according to Dr. Susan Savery, MD, a board-certified obesity medicine and primary care physician with PlushCare, a virtual health platform offering primary care, therapy and weight management services. "Over time, chronic inflammation can be a risk factor for cancer development, as it may damage cell DNA," San Francisco-based Savery, who was not involved in the study, told Fox News Digital. "Our fat cells (adipose tissue) naturally produce inflammatory cells, and GLP-1 medications, similar to bariatric surgery, help reduce this inflammation by decreasing the amount of adipose tissue through weight loss." The study did have some limitations, the researchers acknowledged. "First, it is an observational study. It means that our comparison groups (persons who had surgery versus those who received GLP1-RAs) may still have some residual differences, despite our methodological efforts," Sagy told Fox News Digital. "However, only this type of real-life observational study can provide the long follow-up period that is necessary to evaluate the risk of developing cancer, which often has very long latency periods." Another limitation is that the primary drug included in the study was liraglutide (Saxenda, Victoza), with smaller numbers of people taking exenatide (Byetta) and dulaglutide (Trulicity). "It will be important to evaluate the comparative effectiveness of the newer GLP1-RA drugs, which are expected to have a larger effect," Sagy said. "Although the direction of the results is promising, we should wait and see if and how clinical guidelines will consider it." Reierson agreed that much more research is needed before GLP-1 RAs could ever be considered as cancer prevention options. "Larger, randomized, controlled trials are necessary to confirm the observed effects and better understand the underlying mechanisms," she said. "It will also be important to investigate the impact of GLP-1 RAs on different types of cancer and assess the long-term safety and potential side effects of using GLP-1 RAs as a cancer therapy." Savery agrees that it's likely too early to predict FDA approval for cancer therapy, but noted that "weight reduction plays an important role in cancer prevention, and GLP-1s seem to offer an additional benefit through inflammation reduction." While GLP-1 RAs are "wonderful tools" that can support people on weight-loss journeys, Savery pointed out that maintaining a healthy lifestyle through nutritious eating and regular physical activity is "the foundation for cancer prevention and better overall health."
The Guardian
11-05-2025
- Health
- The Guardian
Weight-loss jabs could halve risk of obesity-related cancers, study finds
Weight-loss jabs could almost halve the risk of obesity-related cancers, a landmark study suggests. Cancer experts said the findings were 'transformational' and could herald a 'whole new era of preventive cancer medicine'. Obesity is associated with 13 different cancers. While losing weight reduces that risk, scientists have calculated weight-loss injections have a bigger protective effect over and above shedding the kilos. Researchers in Israel studied 6,000 adults with no prior history of cancer, who either underwent bariatric surgery or took glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide (Saxenda), exenatide (Byetta) or dulaglutide (Trulicity). The drugs work by mimicking the GLP-1 hormone in the body, which lowers blood sugar levels and makes people feel fuller for longer. Although those who had bariatric surgery lost around double the weight of those on weight-loss medication, the study, presented at the European Congress on Obesity in Malaga, Spain, and published in The Lancet's eClinicalMedicine, found the reduction in cancer risk was broadly the same. Bariatric surgery reduces the risk of cancer by 30-42%, the researchers said. Therefore, accounting for the relative advantage of surgery in reducing patients' weight, the authors found weight-loss drugs were more effective at preventing obesity-related cancer. 'The protective effects of GLP-1RAs against obesity-related cancers likely arise from multiple mechanisms, including reducing inflammation,' said co-lead author Prof Dror Dicker from Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel. Newer drugs could prove even more beneficial, he added. 'New generation, highly potent GLP-1RAs with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers, but future research is needed to make sure these drugs do not increase the risk for non-obesity-related cancers.' A separate study, presented at the conference and published in New England Journal of Medicine, directly compared weight-loss jabs and found patients taking Mounjaro lost about 50% more weight than those taking Wegovy. Patients on Mounjaro typically saw a 20.2% drop in body weight at the end of the trial compared with 13.7% with Wegovy. Responding to the findings, Prof Mark Lawler, an internationally renowned cancer research expert from Queen's University Belfast, said while this was an observational study and caution was needed interpreting the results, the results were very exciting. 'We already know bariatric surgery cuts obesity-related cancer risk by about a third; these data suggest target GLP-1s may cut that risk by nearly 50% – an approach that would be transformational in preventing obesity-related cancer. 'Biologically, this makes sense, as targeting GLP-1 dampens down inflammation, one of the hallmarks of cancer. 'While further work is required on how it works, these data raise the intriguing possibility that a GLP-1 jab could prevent multiple cancers in the general population, including common cancers like breast and colorectal, and difficult to treat cancers like pancreatic and ovarian. This work could herald a whole new era of preventive cancer medicine.' Prof Jason Halford, former president of the European Association for the Study of Obesity and head of psychology at Leeds University, said the drugs should also be tested in patients with newly diagnosed cancers to see if they boosted survival chances. He added the drugs had 'the potential to be a new dawn. And it's not just prevention, weight management in people recently diagnosed with cancer is also critical in terms of outcomes. That would be the next thing to look at. More and more cancers are being associated with obesity.' A team of 54 international experts from 12 different countries issued a joint statement at the conference, calling for weight-loss drugs to be trialled as a priority for cancer prevention. As a result, a UK team of scientists, based at the University of Manchester and funded by Cancer Research UK, are planning a large-scale clinical trial involving tens of thousands of patients, which they hope to get under way within 'three to five years'. Dr Matthew Harris, at the Manchester Cancer Research Centre, said weight-loss jabs 'provide genuinely fantastic weight loss, and may provide an intervention that could be delivered on a population-scale, where we have not been able to achieve this before'.
